AKI severity and management

AKI stage 2 or 3, or GFR decrease > 50%

7 (25.0)

25 (56.8)

.008

Maximal variation of GFR except RRT (N = 57), %

6 [−46 to + 13]

−31 [−49 to −8]

.055

RRT initiated during treatment, n (%)

2 (7.1)

13 (29.5)

.022

Proportion of ICU days with RRT^{a}, %

0 [0–0]

0 [0–13]

.032

Outcomes

Muscular toxicity (CK > 3xUSL), n (%)

4 (14.3)

0
 
Hypersensitivity manifestation, n (%)

0

1 (2)
 
Length of ICU stay^{a,b} (N = 53), days

9 [4–28]

12 [5–25]

.827

Length of inhospital stay^{a,b} (N = 41), days

47 [19–62]

39 [23–52]

.543

28day mortality (N = 71), n (%)

3 (10.7)

11 (25.6)

.124

180day mortality (N = 69), n (%)

10 (35.7)

22 (53.7)

.142
